Host–microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake. Issue 11 (15th December 2016)

• Record Type: Journal Article
• Authors: Pedersen, Camilla; Gallagher, Edith; Horton, Felicity; Ellis, Richard J.; Ijaz, Umer Z.; Wu, Huihai; Jaiyeola, Etana; Diribe, Onyinye; Duparc, Thibaut; Cani, Patrice D.; Gibson, Glenn R.; Hinton, Paul; Wright, John; La Ragione, Roberto; Robertson, M. Denise
• Is Part Of: British journal of nutrition. Volume 116:Issue 11(2016)
• Page Start: 1869
• Page End: 1877
• Publication Date: 2016-12-15
• Subjects: Prebiotic supplements, -- Diabetes, -- Gut microbiota, -- Intestinal permeability, -- Endotoxaemia; Nutrition -- Periodicals; 572.4
• DOI: 10.1017/S0007114516004086
• Languages: English
• ISSNs: 0007-1145

Abstract

Abstract: Aberrant microbiota composition and function have been linked to several pathologies, including type 2 diabetes. In animal models, prebiotics induce favourable changes in the intestinal microbiota, intestinal permeability (IP) and endotoxaemia, which are linked to concurrent improvement in glucose tolerance. This is the first study to investigate the link between IP, glucose tolerance and intestinal bacteria in human type 2 diabetes. In all, twenty-nine men with well-controlled type 2 diabetes were randomised to a prebiotic (galacto-oligosaccharide mixture) or placebo (maltodextrin) supplement (5·5 g/d for 12 weeks). Intestinal microbial community structure, IP, endotoxaemia, inflammatory markers and glucose tolerance were assessed at baseline and post intervention. IP was estimated by the urinary recovery of oral 51 Cr-EDTA and glucose tolerance by insulin-modified intravenous glucose tolerance test. Intestinal microbial community analysis was performed by high-throughput next-generation sequencing of 16S rRNA amplicons and quantitative PCR. Prebiotic fibre supplementation had no significant effects on clinical outcomes or bacterial abundances compared with placebo; however, changes in the bacterial family Veillonellaceae correlated inversely with changes in glucose response and IL-6 levels ( r −0·90, P =0·042 for both) following prebiotic intake. The absence of significant changes to the microbial community structure at a prebiotic dosage/length of supplementation shown to be effective in healthy individuals is an important finding. We propose that concurrent metformin treatment and the high heterogeneity of human type 2 diabetes may have played a significant role. The current study does not provide evidence for the role of prebiotics in the treatment of type 2 diabetes.